Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/Optometrymedimpact Ophthalmic Prostaglandin Prior Auth | Op…
    Ask Trek AI about this page
    CurrentmedimpactPolicy N/A

    Ophthalmic Prostaglandin Analog Prior Authorization Criteria

    Customize your policy alerts

    Sign up for all medimpact policy alerts

    Know when medimpact releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document governs prior authorization criteria and coverage updates for ophthalmic prostaglandin analog agents for Kentucky Medicaid (Fee-for-Service and MCO) members, effective September 1, 2026. It affects pharmacy providers and prescribers submitting PA requests for the listed agents.

    Policy Summary
    Payermedimpact
    PolicyOphthalmic Prostaglandin Analog Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeCoverage criteria revisedstep therapy added
    Effective DateSep 1, 2026
    Next Review Date
    Key ActionObtain prior authorization and document ≥30-day trial and failure of ≥2 preferred prostaglandin agents (or documented allergy/contraindication) before prescribing non-preferred agents.
    SourceLink
    POLICY UPDATE CHANGES

    Prior authorization criteria updated for preferred and non-preferred ophthalmic prostaglandin analog agents, including specified diagnosis requirements and trial/failure requirements.

    Non-preferred agents now require that the patient has had a ≥30-day trial and failure, allergy, contraindication, or intolerance to ≥2 preferred agents.

    Preferred agents require a diagnosis of open-angle glaucoma (and for some agents ocular hypertension is included).

    ≥30drequired trial duration before non-preferred coverage
    2minimum number of preferred agents trialed
    09/01/2026policy effective date
    KYgeographic program affected

    Coverage and Prior Authorization Criteria

    Initial and step therapy coverage criteria

    Coverage updates effective September 1, 2026:

    Preferred agents coverage: Preferred agents (examples: latanoprost; bimatoprost products including Iyuzeh and Lumigan; tafluprost preservative-free; Travatan Z; travoprost) are covered when the patient has a diagnosis of open‑angle glaucoma. For some preferred agents coverage also includes ocular hypertension as indicated in the agent-specific criteria.

    Diagnosis requirement cited in document

    Non-preferred agent coverage

    • Required prior trials: Patient has had at least a 30‑day trial and failure of two or more preferred prostaglandin agents (can be from any sub-class)>= 30 days; >= 2 preferred agents

      Failure, allergy, contraindication (including potential drug–drug interaction), or intolerance to the preferred agents satisfies this requirement

    Policy Summary
    Payermedimpact
    PolicyOphthalmic Prostaglandin Analog Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeCoverage criteria revisedstep therapy added
    Effective DateSep 1, 2026
    Next Review Date
    Key ActionObtain prior authorization and document ≥30-day trial and failure of ≥2 preferred prostaglandin agents (or documented allergy/contraindication) before prescribing non-preferred agents.
    SourceLink
    On This Page
    Coverage and Prior Authorization CriteriaAgent List, Trials, and CodingPrior Authorization, Documentation, and Denial RiskTerms and Agent StatusClinical BackgroundPolicy Changes and Effective Dates

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Exception to trial requirement: OR the patient has documented allergy, intolerance, contraindication (including potential drug–drug interaction) to the required preferred agents

    Documentation of the clinical reason for the exception is required

    Authorization and documentation: Prior authorization is required for the listed ophthalmic prostaglandin analog agents. Documentation must support the diagnosis (e.g., open‑angle glaucoma or ocular hypertension where applicable) and provide evidence of trials/failures or documented contraindications/allergies/intolerances as required by the step therapy rules.

    PA required effective 09/01/2026; see policy for agent list

    Effective 09/01/2026, prior authorization (PA) criteria for the ophthalmic prostaglandin analogs listed in this communication have been updated for Kentucky Medicaid (Fee-for-Service and MCO) members. Pharmacy providers and prescribers should follow the revised coverage rules when submitting PA requests. The document specifies that preferred agents (for example, latanoprost; bimatoprost products; tafluprost; Travatan Z; travoprost) are subject to criteria and are covered when the patient has an appropriate diagnosis such as open-angle glaucoma (and for some agents, ocular hypertension is also an included diagnosis).

    Requests for non-preferred agents (for example, Vyzulta, Xalatan, Xelpros, Zioptan, Zolymbus) will require documentation that the patient has had a trial and failure, allergy, contraindication (including potential drug–drug interactions), or intolerance to at least two preferred agents. The policy requires that prior trials meet the minimum duration of ≥ 30 days before a non-preferred agent will be approved absent documented contraindication or intolerance.

    Agent List, Trials, and Coding

    Listed ophthalmic prostaglandin analog agentsmixed
    LatanoprostPreferred agent (CC, QL)
    bimatoprostPreferred agent (Iyuzeh, Lumigan) (CC, QL)
    tafluprost/PFPreferred agent (CC, QL)
    Travatan ZPreferred agent (CC)
    TravoprostPreferred agent (CC)
    VyzultaNon-preferred agent (AE, CC, QL)
    XalatanNon-preferred agent (CC, QL)
    XelprosNon-preferred agent (CC)
    ZioptanNon-preferred agent (CC, QL)
    ZolymbusNon-preferred agent (CC, QL)
    Preferred agent trial count
    Required number of preferred agents to trialAt least 2 preferred prostaglandin analog agents must be trialed and failed before coverage of non-preferred agents is considered.
    ApplicabilityRequirement applies to requests for non-preferred agents listed in the policy (effective 09/01/2026).
    ExceptionsMay be waived if there is documented allergy, contraindication (including potential drug–drug interaction), or intolerance to preferred agents.
    Trial duration
    Minimum trial durationA trial of at least 30 days (≥ 30-day) is required for each preferred agent considered failed before non-preferred agents will be covered.
    DocumentationDocumentation of the ≥30-day trial and the reason for failure (lack of efficacy, intolerance, allergy, or contraindication) must be provided for PA requests.
    Effective dateRequirement effective September 1, 2026 for Kentucky Medicaid members.

    Prior Authorization, Documentation, and Denial Risk

    Prior Authorization

    Prior authorization required (effective 09/01/2026)

    Prior authorization (PA) is required for the ophthalmic prostaglandin analog agents listed in this update. This PA requirement is effective September 1, 2026, and applies to the agents identified in the policy.

    Step Therapy

    Step therapy: trial ≥2 preferred agents (≥30 days)

    Step therapy applies before coverage of non-preferred prostaglandin analogs: the patient must have trialed and failed at least two preferred agents for a minimum of 30 days each unless an exception applies.

    • Trial and failure of >= 2 preferred agents any sub-class
    • Each trial must be >= 30 days
    • Exceptions allowed for documented allergy, intolerance, contraindication (including drug–drug interactions)
    Documentation Required

    Required documentation for PA requests

    Document the clinical justification submitted with PA requests: include the patient’s diagnosis and objective evidence supporting trials/failures or an applicable contraindication, allergy, or intolerance to preferred agents.

    • Diagnosis (e.g., open‑angle glaucoma, or ocular hypertension where specified)
    • Evidence of trials and failures of preferred agents (duration and outcome)
    • Documentation of allergy, intolerance, contraindication or clinically relevant drug–drug interaction when claiming an exception
    Denial Risk

    Denial risk for non‑preferred agents without required documentation

    Requests for non-preferred agents are subject to denial if required trials or an approved exception are not documented.

    • Denial risk if there is no documentation of ≥30‑day trials and failures of ≥2 preferred agents
    • Denial risk if there is no documentation of allergy, intolerance, contraindication, or relevant drug–drug interaction when used to justify bypassing step therapy

    Terms and Agent Status

    Preferred agents
    LatanoprostListed as a preferred agent (subject to criteria).
    Bimatoprost productsListed as preferred agents (Iyuzeh, Lumigan) subject to criteria.
    Tafluprost (preservative-free)Listed as a preferred agent (tafluprost/PF) subject to criteria.
    Travatan ZListed among preferred agents subject to criteria.
    TravoprostListed as a preferred agent subject to criteria.
    Non-preferred agents and trial requirement
    VyzultaClassified as a non-preferred agent (AE, CC, QL). Requires prior trial/failure of ≥2 preferred agents for coverage.
    XalatanClassified as a non-preferred agent (CC, QL). Requires prior trial/failure of ≥2 preferred agents for coverage.
    XelprosClassified as a non-preferred agent (CC). Requires prior trial/failure of ≥2 preferred agents for coverage.
    ZioptanClassified as a non-preferred agent (CC, QL). Requires prior trial/failure of ≥2 preferred agents for coverage.
    ZolymbusClassified as a non-preferred agent (CC, QL). Requires prior trial/failure of ≥2 preferred agents for coverage.

    Clinical Background

    Ophthalmic prostaglandin analogs are topical medications used to lower intraocular pressure and are commonly prescribed for conditions such as open-angle glaucoma and ocular hypertension. The update clarifies which agents are designated as preferred versus non-preferred for Kentucky Medicaid and establishes step-therapy expectations: prior authorization is required for the listed agents, and coverage of non-preferred products is contingent on documented trials of preferred agents per the criteria effective September 1, 2026.

    Policy Changes and Effective Dates